2. Resumen de Caso
39 anos
Gestas: 3
Partos: 3
No desea tener mas hijos
Ciclo regular: 31 por 4
Flujo menstrual: 3 cruces
P.F: MELA
01/06/2013 2
3. Dismenorrea: 3 cruces
Diabetes mellitus tipo 2
Hipertension Arterial tratada hace 2 anos
Miomatosis Uterina
Habitos: Fuma desde hace 15 anos, 15 unidades
por dia
Ingiere alcohol esporadicamente
01/06/2013 3
15. Seleccion del Medicamento
01/06/2013 15
Farmaco Eficacia Seguridad Adecuacion Coste Total
Comodidad Cumplimiento otros
Etonoge
strel
implante
3 2 2 3 0 2 12
medroxy
progestero
ne acetate
2 2 1 1 0 1 7
16. IP de IMPLANON (etonogestrel)
IMPLANON®
is an off-white nonbiodegradable
etonogestrel-containing single sterile rod
implant for subdermal use.
containing 68 mg of the synthetic progestin
etonogestrel
01/06/2013 16
17. The release rate is 60 to 70 mcg/day in Week 5
to 6
35 to 45 mcg/day at the end of the first year
30 to 40 mcg/day at the end of the second year
25 to 30 mcg/day at the end of the third year.
01/06/2013 17
20. Distribution
The apparent volume of distribution averages
about 201 L. ENG is approximately 32% bound
to sex hormone binding globulin (SHBG) and
66% bound to albumin in blood.
Metabolism
is metabolized in liver microsomes by the
cytochrome P450 3A4 isoenzyme.
01/06/2013 20
21. Excretion
The elimination half-life of ENG is
approximately 25 hours. Excretion of ENG and
its metabolites, is mainly in urine and to a
lesser extent in feces. After removal of
IMPLANON, ENG concentrations decreased
below sensitivity of the assay by 1 week.
01/06/2013 21
22. INDICATIONS AND USAGE
IMPLANON® (etonogestrel implant) is indicated
for women for the prevention of pregnancy.
IMPLANON is a long-acting (up to 3
years), reversible, contraceptive method.
IMPLANON must be removed by the end of the
third year and may be replaced by a new
IMPLANON
01/06/2013 22
23. Contraindications
Known or suspected pregnancy
Current or past history of thrombosis or
thromboembolic disorders
Hepatic tumors (benign or malignant), active liver
disease
Undiagnosed abnormal genital bleeding
Known or suspected carcinoma of the breast or
personal history of breast cancer
Hypersensitivity to any of the components of
IMPLANON
01/06/2013 23
24. PRECAUTIONS
This product does not protect against infection
from HIV or other sexually transmitted
diseases.
Carbohydrate and Lipid Metabolic Effects
Weight Gain
Liver Function
Depression
Contact Lenses
Drug Interactions 24
25. OVERDOSAGE
Overdosage may result if more than 1
IMPLANON® (etonogestrel implant). In case of
suspected overdose, IMPLANON should be
removed.
01/06/2013 25
26. DOSAGE AND ADMINISTRATION
To minimize the risk of neural or vascular
damage, IMPLANON should be inserted at the
inner side of the nondominant upper arm about
8 to 10 cm (3–4 inches) above the medial
epicondyle of the humerus.
IMPLANON should be inserted subdermally just
under the skin, between the triceps and biceps
muscles.
01/06/2013 26
